Ensemble and Alexion, Novartis

Company: Ensemble
Partners: Alexion ($ALXN), Novartis ($NVS)
Technology: Ensemblins
Amount: Alexion, undisclosed; Novartis, undisclosed

The scoop: Both Alexion and Novartis snagged a piece of Ensemble Therapeutics in 2013, each locking down a partnership with the creator of Ensemblin technology, which is designed to make biologics deliverable orally as opposed to by injection. For this, Alexion and Novartis both signed on for undisclosed amounts. Considering Ensemble pulled in $186 million from Boehringer Ingelheim in 2012, odds are these were decent-sized deals.

Harvard professor and Howard Hughes Medical Institute Investigator David Liu's work provided the foundation for Ensemble, and Liu is still involved with the company. Ensemble promises a simpler delivery route for biologics that can traditionally be taken only via injection. The technology is in its very early stages, but the idea is one that interests big players in the industry.

Also on Ensemble's partner list from years prior are Pfizer ($PFE), Bristol-Myers Squibb ($BMY) and Genentech.

For more:
Booming Alexion looks to Ensemble program for ultrarare disease programs
Novartis grabs lead IL-17 program as Ensemble adds another marquee deal

Ensemble and Alexion, Novartis
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.